AbCellera Biologics Inc. beat EPS estimates 56% of the time across 16 reported quarters (9 beats, 7 misses), averaging +5.7% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.17 | $-0.18 | -5.9% | Miss | |
| Q1 FY26 | $-0.22 | $-0.14 | +36.4% | Beat | Q1 FY26 call · transcript |
| Q4 FY25 | not reported | $-0.03 | not reported | not reported | |
| Q3 FY25 | $-0.17 | $-0.19 | -11.8% | Miss | |
| Q2 FY25 | $-0.17 | $-0.12 | +29.4% | Beat | |
| Q1 FY25 | $-0.17 | $-0.15 | +11.8% | Beat | |
| Q4 FY24 | $-0.15 | $-0.11 | +26.7% | Beat | |
| Q3 FY24 | $-0.14 | $-0.17 | -21.4% | Miss | |
| Q2 FY24 | $-0.15 | $-0.13 | +13.3% | Beat | |
| Q1 FY24 | $-0.16 | $-0.14 | +12.5% | Beat | |
| Q4 FY23 | $-0.14 | $-0.17 | -21.4% | Miss | |
| Q3 FY23 | $-0.14 | $-0.10 | +28.6% | Beat |
Back to ABCL overview · ABCL holders · ABCL KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.